stockrow
Saturday 7 November 2026
Export CCCC’s income statement to Excel — free account
C4 Therapeutics, Inc.
CCCC Healthcare Biotechnology
C4 Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $35.9 million, up 1.02% from fiscal 2024.
- Revenue
- −24.6%
- EPS
- +63.6%
- Free cash flow
- +17.9%
Quarter to September 2026, against a year earlier
3.12
0.17
+5.76%
Follow CCCC
Alert me
C4 Therapeutics, Inc. (CCCC) P/E ratio
C4 Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 9.6× (September 2021) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 0.0× | — |
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| 24 more quarters | Free account |
Against its own ten years
Low 0.0×
High 9.6×
Ten-year median
0.0×
Current reading's percentile
92
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ZURA Zura Bio Limited compare | n/m |
| TECX Tectonic Therapeutic, Inc. compare | n/m |
| CTNM Contineum Therapeutics, Inc. compare | n/m |
| RZLT Rezolute, Inc. compare | n/m |
| ALLO Allogene Therapeutics, Inc. compare | n/m |
| CCCC C4 Therapeutics, Inc. | n/m |
| AVTX Avalo Therapeutics, Inc. compare | n/m |
| LYEL Lyell Immunopharma, Inc. compare | n/m |
| TRXB TRex Bio Inc. compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)